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I NTRO D U CTlON 
Candidemia used to be a rare disease limited to patients 
with burn wounds and other severe trauma. Cundida 
spp were therefore classified as harmless commensals. 
During the past decades, the enlarging proportion of 
patients in need of chemotherapy, transplant surgery 
and intensive care, was paralleled by a steady increase in 
the incidence of nosocomial Cundidu infections [I ,2]. 
In US hospitals, the incidence of candidemia increased 
by two- to fivefold and one- to fourfold in teaching and 
non-teaching hospitals, respectively [3,4], with Cundidu 
spp being the fourth or even third most common 
pathogen isolated from blood cultures [4,5]. 
Despite antifungal treatment, the mortality of 
candidemia is still as high as 60%, with an attributable 
mortality of 38% (CI95: 26-49) [6]. In those patients 
surviving candidemia the average hospital stay is 
prolonged by 30 days, compared to patients without 
Cundidu infections [6]. Candidemia, therefore, is not 
only a life-threatening yeast infection, but furthermore 
significantly increases the costs of health care. 
Candidemia remains a difficult entity to treat. The 
need to adopt treatment to the individual patient 
hinders the development of uniform therapeutic re- 
commendations. Regarding the frequency of hemato- 
genous dissemination, its high mortality, and the 
difficulties in establishing accurate bedside diagnosis, all 
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patients with candidemia should be treated regardless of 
its source or duration [6-lo]. Terms such as ‘benign’ 
candidemia should be abandoned. The question 
remains as to which antifungal to use, in which doses, 
for how long, and whether it should be given alone or 
in combination. In patients with catheter-related 
candidemia, the removal of the indwelling device seems 
essential to eradicate the yeasts [9,11]. Failure to 
complete catheter exchange was strongly associated 
with the persistence of candidernia in a study by Rex 
et al. [12]. 
ANTIFUNGALS USED IN THE TREATMENT OF 
CANDIDEMIA AND DEEP-SEATED INFECTIONS 
Until recently, there have been very few systemic 
antifungals, and amphotericin B was considered as the 
standard. However, clinicians were reluctant to use the 
drug since they were appalled by its adverse effects. Due 
to its ease of administration and safety fluconazole 
seemed promising but, until confirmed by Rex et al. 
[13], it was unknown whether amphotericin B and 
fluconazole are similarly effective in the treatment of 
non-neutropenic patients with primarily catheter- 
related candidemia. Fluconazole was furthermore 
proven to be effective for various candidal infections, 
including renal disease, hepatosplenic candidosis, and 
deep-organ candidosis in organ-transplant recipients 
and patients with hematological malignancies [14-181. 
In surgical patients the combination of amphotericin B 
(0.5 iiig/kg) and flucytosine (3 x 2.5 g) led to an earlier 
microbiological response, but cure rates were identical 
to those of fluconazole monotherapy [19]. With the 
probable exception of acute hematogenous candidosis 
in neutropenic patients all (tri)azoles can be effective 
alternatives to amphotericiri B (f-flucytosine) for 
selected systemic candidal infections. 
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Arnphotericin B 
The polyenes include three main compounds: 
natamycin, nystatin, and amphotericin B, of which 
only the last can be used parenterally in the treatment 
of systemic fungal infections. Amphotericin B is a 
naturally occurring compound produced by Strepto- 
myces nodostrs. It became the treatment of choice in 
patients with candidemia and deep-seated infections, 
aspergillosis and mucormycosis immediately after its 
introduction in the late 1950s. The clinical effect of 
amphotericin B is due to its irreversible binding to 
ergosterol of the fungal cell membrane. The major 
disadvantage of the conventional formulation of 
amphotericin B is the high incidence of adverse 
reactions, often leading to early termination of 
treatment (Table 1). The total dose of conventional 
amphotericin B is limited to 4 g since renal tubular 
damage is predictable in patients exceeding this dose. 
Meanwhile, some of the early adverse reactions might 
be prevented by slow build up of dosage or co- 
administration of antihistamines, but the major 
problem of nephrotoxicity remains almost unchanged. 
Characteristics of amphotericin B and the other 
antifungal agents used in the treatment of systemic 
candidosis are shown in Table 2. Considerable effort has 
been expanded in the quest for less toxic drug 
analogues and different formulations. Various prepar- 
ations of the new ampholiposomes are currently under 
investigation. All the various lipid formulations of 
amphotericin B seem to be different with regard to 
their pharmacokinetic properties, toxicity and anti- 
fungal effects. In general, these formulations achieve 
higher levels of amphotericin B in liver and spleen 
(accumulation), whereas lower levels are found in 
kidney and serum. Liposomal amphotericin B prepar- 
ations were shown to reduce significantly the toxicity 
and be equally effective, using a dosage of up to five 
times that of the conventional amphotericin B [20]. 
The optimal dosage of these products is still unknown. 
So far, it is suggested that higher dosages would be 
Table 1 Adverse effects of antifungal agents used in the treatment of systemic candidosis 
Organ system Amphotericin B Flucytosine Ketoconazole Fluconazole Itraconazole 
GI tract nausea 
vomiting 
anorexia 
diarrhea 
abdominal pain 
Skin rash 
pruritus 
Stevens-Johnson syndrome 
Liver elevation plasma aminotransferase 
hepatitis 
Bone marrow anema 
leukopenia 
thrombocytopenia 
Kidney azotemia 
tubular acidosis 
hypokalemia 
hypomagnesemia 
Endocrine hypokalemia 
system adrenal insufficiency 
decreased libido 
impotence 
gynecomastia 
hypertension 
edema 
Other (thrombo)phlebitis 
headache 
fever and chills 
confusion 
photophobia 
seizure 
dizziness 
+ 5% 
+ 5% 
+ 
+ 
+ 
+ + 
+ 
+ 
7% 
rare 
less common 
+ 
+ 
<lo% <5% <lo% 
<lo% <5% <lo% 
+ 
+ 
+ 
+ 
+ 
+ 
t 
2-10% 1-7% 1-5% 
+ rare rare 
80% 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
rare 
+ 
+ 
+ 
+ 
+ 
t 
rare 
+ 
+ 
+ 
+ 
+ 
+ 
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Table 2 Characteristics of antifungal agents used in the treatment of systemic candidosis 
Characteristics Amphotericin B Flucytosine Ketoconazole Fluconazole Itraconazole 
Trade name 
Formulation 
Fungizone@ Ancotil@ Nizoral" 
iv po or iv Po 
Oral bio-availability -. 
Protein binding ++ 
Unchanged drug in urine _ _  
Peak plasma concentration (mg/L) 1.2-2.0 
CSF concentration _ _  
Terminal elimination half-life 
Dialysable 
Renal insufficiency 
Supplemental dose after H D  
Contraindication 
Increases plasma 
concentration of: 
Decreasing azole plasma 
concentration 
Resistance 
Dosage: 
Adults 
Dosage: 
Children 
20-24 h 
(end-phase 15 d) 
HD- 
PD - 
no adjustment 
necessary 
not required 
potential renal failure 
severe hepatic failure 
C. lusitaniac 
++ + 
pH dependent 
_ _  ++ 
++ _ _  
++ - 
30-45 1.5-3.1 
3-6 h 
H D  + 
PD + 
extend interval 
37.5 mg/kg q6 h 
pregnancy, 
neonates 
up to 50% 
primarily resistant 
37.5 ing/kg q6 h 
Trisporal" 
po* (iv under 
investigation) 
Diflucanm 
po* or iv 
++ + 
pH dependent 
_ _  ++ 
++ _ _  
++ _ _  
10.2 0.2-0.4 
7-10 h 22-31 h 
HD- H D  + 
PD - PD ? 
no adjustment CrCl < 40 mL/ 
necessary min 200 mg, 
CrCl <20 niL/min 
100 mg/24 h 
not required 200 mg 
pregnancy, pregnancy, 
lactation lactation 
cyclosporin cyclosporin 
cumarines cumarines 
phenytom phenytoin 
antacids rifanipin 
Hz-antagonist 
isoniazid 
phenytoin 
rifampin 
C. krusei C. krusei 
C. glabrata C. $brats 
200400 mg q24 h 200-400 mg 
q24 h, initially 
once 400 mg 
0.6-1 mg/kg 
per day q24 h 
(daily increase of 
0.1-0.25 mg/kg, 
maximum total 
dose: 5 g) 
0.6-1 mg/kg 37.5 nig/kg q6 h 3.3-6.6 mg/kg 6-12 mg/kg q24 h 
per day 
24-42 h 
H D  - 
P1>? 
not required 
pregnancy, 
lactation 
cyclorporin 
cumarinec 
(phenytoin) 
(digox] n) 
antacids 
Hz-antagonist 
phenytoin 
rifampin 
200 q12 h 
Comments bladder irrigation use in combination antagonism with penetrates well 
10-50 mg/L with other antifungals AmB into CSF 
intrathecal: 0.2-0.5 nig not recommended 
q48-72 h (diluted with 
CSF or glucose) infection 
add heparin to reduce 
thrombophlebitis 
for systemic 
*tablets and suspension 
-- no/very low, - low, +/- middle, + = high, ++ very high, H D  = hemodialysis PD = peritoneal dialysis 
necessary since compared with standard amphotericin 
B, serum concentrations may be lower after the same 
doses of the liposomal formulation. Furthermore, the 
non-liposomal amphotericin B was shown to be truth in clinical practice. 
superior on a 'nlilligram per kilogram' basis in animal 
models. Recent data of the EORTC (submitted for 
publication) suggest that this theory probably holds no 
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Flucytosine 
Flucytosine inhibits the protein synthesis of yeasts. The 
penetration of the drug into body cavities, including 
the cerebrospinal fluid, is good, but its clinical use is 
limited by the common occurrence of primary 
resistance and development of resistance during treat- 
ment. Furthermore, flucytosine can suppress the bone 
marrow, especially limiting its use in AIDS patients. 
Flucytosine in combination with (reduced dosage) 
amphotericin B was shown to be effective in patients 
with persistent candidemia and/or deep-seated candi- 
dosis involving the liver, spleen, bones, CNS, or the 
heart [21]. 
h o l e s  
The azoles are divided into the older imidazoles 
(miconazole and ketoconazole) introduced in the early 
1980s, and the newer triazoles, fluconazole and itra- 
conazole, introduced in 1990 and 1992, respectively. 
The main antifungal effect of the azoles is through 
inhibition of the ergosterol synthesis, thereby inter- 
acting with the main sterol in the fungal cell 
membrane, leading to an increased permeability and 
obstruction of cell growth. 
In contrast to fluconazole, the bioavailability and 
absorption of oral ketoconazole and itraconazole is 
influenced by the stomach pH, thereby altered by the 
presence of food or gastric acid [22]. Ketoconazole 
and itraconazole are almost exclusively excreted in 
feces and urine, after metabolisation in the liver. The 
proportion of the drugs excreted unchanged via the 
urine is so little that doses need not be adjusted in 
patients with renal impairment. In contrast, flucona- 
zole doses must be reduced in patients with a 
glomerular filtration rate of <50 mllminute, since 
80% of the administered dose is excreted unchanged 
in the urine. The most important drug interactions are 
listed in Table 2. Since ketoconazole, and rarely the 
triazoles, may cause clinically important, even fatal 
hepatitis, azole therapy should always be discontinued 
in patients with symptoms or laboratory evidence of 
hepatic dysfunction [23-251. In general, the azoles, 
especially the triazoles, are a safe and effective 
alternative to amphotericin B for the treatment of 
systemic C a n d i d a  infections. In patients with keto- 
conazole-refractory candidosis in vitro cross resistance 
to triazole antifungals and, in one case, clinical 
treatment failures were demonstrated [26]. The 
development of resistance and/or selection of primary 
resistant Cand ida  spp might be potentially problematic 
during treatment with azole antifungals. 
In the newest treatment options, such as the lipid 
or liposomal preparations of amphotericin B, not only 
must the clinical effect be determined, but furthermore 
the economic implications, since these preparations are 
extremely expensive. Next to liposomal amphotericin 
B, a huge variety of new azoles, pneumocandind 
echinocandins, liposomal formulation of other anti- 
fungals, and new dosages of clinically used antifungals 
(1600 mg fluconazole) are currently under (clinical) 
investigation (Table 3). 
The use of amphotericin B in combination with 
azole antifungal drugs (mainly fluconazole) is increas- 
ingly seen in clinical practice or even recommended by 
experts. Animal model studies of Candida and Crypto-  
cuccus spp infections provide evidence for the lack 
of antagonism (or even additive effects) of several 
polyene-azole combinations, but the interaction may 
vary by fungus, test model, and drug [27]. Presently, 
routine use of this combination should not be recom- 
mended. 
EMERGENCE OF NON-CANDIDA ALBICANS SPP 
AND ANTIFUNGAL RESISTANCE 
As mentioned above, C. albicans used to be-and to a 
lesser degree still is-the Cand ida  species predomin- 
antly isolated from clinically important sites. Recently, 
infections are increasingly caused by other Candida spp, 
such as C. tropicalis, C. parapsilosis, C. krusei and C. 
glabrata [28,29]. In some institutions the proportion of 
non-albicans Cand ida  isolates actually exceeded that of 
C. albicans [30]. 
With the exception of C. tropicalis the virulence of 
non-albicans species seems to be comparable to that o j  
C. albicans [31]. The increase of C. tropicalis infection in 
patients with leukemia is probably due to a higher 
virulence of this species in this patient group, in whom 
the gastrointestinal mucosal ‘barrier’ is damaged 
through the use of cytarabine [32]. Despite its high 
virulence (colonization with C. tropicalis frequently leads 
to invasive infections) the mortality of C. tropicalis 
candidemia was shown to be lower than that of C. 
albicans [33]. Certainly, more studies are needed to 
further evaluate the pathogenicity of C. tropicalis and 
the other non-albicans species. Presently, all Cand ida  
spp isolated from clinically relevant material should be 
classified as possible pathogens. 
With the recent clinical use of new azole com- 
pounds not only is a shift among the Cand ida  spp 
involved in nosocomial infections discussed, but also 
the development of resistance [34]. Apart from the 
extensive use of new antifungals, and the changing 
patient population, the application of standardized 
antifungal susceptibility tests and the use of molecular 
typing methods may be other reasons to explain the 
current epidemiological trend. In addition, the use of 
these methods allows us to better understand the 
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Table 3 New and future antifungal agents 
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Generic Trade name* Comment 
Liposonial amphotericin B 
Aniphotericin 13 Lipid Complex 
AniB colloidal dispersion 
Long-circulating pqqlated A d  liposonies 
Liposomal nystatin iv 
Terbinafine 
Itraconazole iv 
Fluconazole - high dose 
UK-109.496 
Sch 510448 
MK-0991 
UR-9746 and UR-9751 
BMS-18118 
Syringomycin E 
Investigation stopped 
D 807 
D 8581 
LY 121.019 (cilofungin) 
LY 303366 
A d i s o m e "  
Abelcet@ 
Amphocil" 
Nyotranm 
Lamisil@ 
Trisporal" 
Diflucan@ 
voriconazole@ 
stopped 
stopped 
stopped 
stopped 
licensed, unilamellar liposonial vesicle 
licensed, sheets 
licensed, niicelle 
tested in viti-o 
clinical phase I studes 
old p.0. drug new indications ? under clinical invectigation 
triazole, under clinical inve5tigation 
under clinical investigation 800-1 600 mg/day 
triazole, under clinical investigation 
azole, clinical investigation coming 
pneumoncandin, under clinical investigation 
triazole, tested in vitro 
pradimicin, tested in vitro 
lipodepsipeptide, tested in vitro 
triazole, tested in vitro 
triazole, tested in vitro 
Clinical evaluation stopped for toxlc reasons 
echinocandin B antifungal, clinical trials started but 
stopped for 'coiiimercial reasons' 
epidemiology of candidosis, but we are furthermore 
able to prove the development of resistance in 
sequential isolates of individual patients receiving 
antifungal treatment. 
Resistance of Candida spp. to amphotericin B 
appears to be extremely uncommon. Immunocompro- 
mised patients with candidemia due to isolates with 
amphotericin B MIC of N . 8  mg/L, were shown to 
have a significantly higher mortality, compared to those 
whose Candida blood-culture isolates had an MIC of 
less than 0.8 mg/L [35]. Aside from these reports, 
primary resistance and development of resistance to 
amphotericin B is well documented in C. bsitaniae 
[36,37]. Amphotericin B-resistant C. lusitaniae are 
increasingly isolated from hematology patients in 
the US, where amphotericin B is heavily used in the 
prophylaxis of this patient group [29]. Recently, the 
development and spread of amphotericin B (and 
5-fluorocytosine-resistant) C. lusitaniae strains within 
the hospital environment were reported [38-411. 
Meanwhile amphotericin B, due to its toxicity and 
cumbersome administration, was restricted to patients 
with severe fungal infections; fluconazole is widely used 
for the (early) treatment of candidosis, possibly leading 
to resistance development or a shift towards non- 
albicans species. Furthermore, it is applied over long 
periods or even continuously in AIDS patients with 
remittent oropharyngeal candidosis. Subsequently, 
fluconazole resistance was not only first reported in this 
setting [42-471, but is still hardly ever seen outside this 
group [48]. Most of these cases were advanced AIDS 
patients who had notable prior exposure to flucona- 
zole. Resistant isolates generally had an elevated 
fluconazole MIC and were genotypically identical with 
the initial isolate, although reinfection during treatment 
with a genotypically different isolate may occur [42,49]. 
In those cases where development of fluconazole resis- 
tance occurred, patients suffered fi-om long-lasting 
neutropenia, infections with intrinsically resistant 
strains, such as C. Kvtrsei, failure to remove a potentially 
infected device, or they received low-dose (100- 
200 mg/day) treatment [48,50-52]. In a randomized 
multicenter trail of fluconazole versus amphotericin €3 
as treatment of non-neutropenic patients, no significant 
increase in MIC among serial isolates from individuals 
with persistent Candida infections could be demon- 
strated [52]. Therefore, in patients, other than those 
(AIDS patients) with recurrent oropharyngeal candi- 
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dosis, who receive shorter courses of therapy the 
chances of resistance development are very low [52]. A 
good clinical response to fluconazole treatment can stdl 
be expected, especially if an appropriate dose (2400 
mg/day) is given, and intrinsically resistant species, such 
as C. krcrsei, are ruled out. 
In general, available data illustrate the possibility of 
resistance development during fluconazole treatment 
and selection ofinherently resistant strains [48]. It seems 
that the shift from albicans to non-albicans species, 
respectively, from susceptible to less susceptible or 
resistant Cand ida  strains, is limited to a small group of 
severely immunocompromised patients, and patients 
treated for extended periods, or receiving long-term 
prophylaxis with less than 200 mg/day. Furthermore, 
other factors influence this shift, since some investig- 
ators could not demonstrate any association between 
the use of azole antifungals and the emergence of non- 
albicans species [53,54]. Despite the growing percep- 
tion of azole resistance and shifting proportions of 
Cand ida  spp as clinically relevant pathogens, the true 
incidence of the problem and strategies to prevent it are 
still unclear. 
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